Parp inhibitors - Study guides, Class notes & Summaries

Predictors of PDL1/PD1 inhibitor response Presence of tumor CD8 cell infiltration High cancer genome burden High levels of cancer PD-L1 expression (PD1 is on the cytotoxic T cell) Ipilimumab CTLA4 inhibitor Nivolumab PD-1 inhibitor Regorafenib VEGF inhibitor Bevacizumab Monoclonal antibody against VEGF-A. Inhibits angiogenesis. Pembrolizumab PD-1 inhibitor Atezolizumab PD-L1 inhibitor Avelumab PD-L1 inhibitor Durvalumab PD-L1 ...

Hereditary Breast and Ovarian Cancer (HBOC) Review Exam Questions & Answers How much breast and ovarian cancer is hereditary? - ANSWER-5-10% for breast cancer 10% for ovarian cancer 15-20% of breast cancers are familial clusters Autosomal Dominant High penetrance Breast cancer genes/Conditions - ANSWER-HBOC: BRCA1 and 2 Li-Fraumeni Syndrome: TP53 Cowden Syndrome: PTEN PALB2 Associated Cancer syndromes Hereditary Diffuse Gastric Cancer: CDH1 Peutz Jaeger Syndrome: STK...

Predictors of PDL1/PD1 inhibitor response Presence of tumor CD8 cell infiltration High cancer genome burden High levels of cancer PD-L1 expression (PD1 is on the cytotoxic T cell) Ipilimumab CTLA4 inhibitor Nivolumab PD-1 inhibitor Regorafenib VEGF inhibitor Bevacizumab Monoclonal antibody against VEGF-A. Inhibits angiogenesis. Pembrolizumab PD-1 inhibitor Atezolizumab PD-L1 inhibitor Avelumab PD-L1 inhibitor Durvalumab PD-L1 inhibitor Cemiplimab PD-1 inhibitor fo...

ONS/ONCC Chemotherapy/Immunotherapy Lesson 11: Targeted Therapies How targeted therapy and chemo differ - ANS -targeted therapies act on specific molecular targets on or within the cells that are associated with cancer, whereas standard chemo act on all rapidly dividing cells-chemo has more SEs-targeted therapy ae chosen and designed to interact with their target on or within the cells, whereas chemo were IDed becaused they kill cells-targeted therapies are often cytostatic (th...

T/F: self suffciency in growth signals is a hallmark of cancer - True T/F: enhanced sensitivity to anti-growth signals is a hallmark of cancer - False T/F: tumor promoting inflammation is a hallmark of cancer - True T/F: limited replicative potential is a hallmark of cancer - False Genomic instability and mutation - PARP inhibitors Enabling replicative immortality - telomerase inhibitors Avoiding immune detection - immune activating anti-CTLA4 mAb Sustaining prolifera...

Immunotherapy / Chemotherapy Exam With 100% Verified And Correct Answers 2024

Erlotinib - An inhibitor that targets epidermal growth factor receptor (EGFR) Midostaurin - Targets FLT3 receptor Transuzumab - Monoclonal antibody targeting human epidermal growth factor receptor 2 (HER2) Topoisomerases - Epirubicin Histone Deacetylase (HDAC) - Romidepsin (Rubraca) Panobinostat (Farydak) Belinostat (Beleodaq) Poly ADP ribose polymerase (PARP) - Rucaparib (Rubraca) Olaparib (Lynparza) Niraparib (Zejula) CDK4 and CDK6 Inhibitors - Palbociclib (Ibranc...